4 news items
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
Equivalents & Marketable Securities, as of March 31, 2024, Pro Forma for $160 Million Reimbursement Payment and Debt Repayment
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
GOSS
6 May 24
as a development reimbursement. Additionally, Gossamer will be eligible to receive up to $146 million in regulatory milestones and $180
Gossamer Bio Secures $160M Partnership with Chiesi Group to Accelerate Development of Pulmonary Hypertension Treatment, $486M Potential for Seralutinib Collaboration
GOSS
6 May 24
reimbursement. Additionally, Gossamer will be eligible to receive up to $146 million in regulatory milestones and $180 million in sales milestones.
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones
- Prev
- 1
- Next